(2E,Z)-2-[(4-chlorophenyl)thio]-3-(dimethylamino)-1-[4-(methylsulfonyl)phenyl]prop-2-en-1-one | 1199804-72-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2E,Z)-2-[(4-chlorophenyl)thio]-3-(dimethylamino)-1-[4-(methylsulfonyl)phenyl]prop-2-en-1-one
• 英文别名: 2-[(4-Chlorophenyl)thio]-3-(dimethylamino)-1-[4-(methylsulfonyl)phenyl]prop-2-en-1-one；2-(4-chlorophenyl)sulfanyl-3-(dimethylamino)-1-(4-methylsulfonylphenyl)prop-2-en-1-one
• CAS: 1199804-72-2
• 化学式: C₁₈H₁₈ClNO₃S₂
• 分子量: 395.931
• InChiKey: JMSZIZGPJXZNQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  88.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2E,Z)-2-[(4-chlorophenyl)thio]-3-(dimethylamino)-1-[4-(methylsulfonyl)phenyl]prop-2-en-1-one 在 trans-N,N'-dimethyl-1,2-cyclohexyldiamine 、 potassium phosphate 、 copper(l) iodide 、 一水合肼 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 0.5h， 生成 4-((4-chlorophenyl)thio)-1-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-1H-pyrazole
  参考文献：
  名称：

  Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain

  摘要：

  We report herein the identification of MK-4409, a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. Starting from a high throughput screening (HTS) hit, medicinal chemistry efforts focused on optimizing of FAAH inhibition in vitro potency, improving the pharmacokinetic (PK) profile, and increasing in vivo efficacy in rodent inflammatory and neuropathic pain assays.

  DOI：

  10.1021/ml5001239
• 作为产物：
  描述：

  2-溴-1-(4-甲磺酰基)苯乙酮 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 96.67h， 生成 (2E,Z)-2-[(4-chlorophenyl)thio]-3-(dimethylamino)-1-[4-(methylsulfonyl)phenyl]prop-2-en-1-one
  参考文献：
  名称：

  Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain

  摘要：

  We report herein the identification of MK-4409, a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. Starting from a high throughput screening (HTS) hit, medicinal chemistry efforts focused on optimizing of FAAH inhibition in vitro potency, improving the pharmacokinetic (PK) profile, and increasing in vivo efficacy in rodent inflammatory and neuropathic pain assays.

  DOI：

  10.1021/ml5001239

文献信息

• [EN] PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS DE PYRAZOLE UTILES COMME INHIBITEURS DE FAAH
  申请人：MERCK & CO INC

  公开号：WO2009151991A1

  公开（公告）日：2009-12-17

  The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease

  本发明涉及某些咪唑衍生物，其可用作脂肪酰胺水解酶（FAAH）的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH
  申请人：Lin Linus S.

  公开号：US20110144056A1

  公开（公告）日：2011-06-16

  The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease

  本发明涉及某些咪唑衍生物，它们可用作脂肪酸酰胺水解酶（FAAH）的抑制剂。本发明还涉及包含这些化合物作为活性成分的制药组合物，以及这些化合物及其制剂在治疗某些疾病中的应用，包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain
  作者：Harry R. Chobanian、Yan Guo、Ping Liu、Marc D. Chioda、Selena Fung、Thomas J. Lanza、Linda Chang、Raman K. Bakshi、James P. Dellureficio、Qingmei Hong、Mark McLaughlin、Kevin M. Belyk、Shane W. Krska、Amanda K. Makarewicz、Elliot J. Martel、Joseph F. Leone、Lisa Frey、Bindhu Karanam、Maria Madeira、Raul Alvaro、Joyce Shuman、Gino Salituro、Jenna L. Terebetski、Nina Jochnowitz、Shruti Mistry、Erin McGowan、Richard Hajdu、Mark Rosenbach、Catherine Abbadie、Jessica P. Alexander、Lin-Lin Shiao、Kathleen M. Sullivan、Ravi P. Nargund、Matthew J. Wyvratt、Linus S. Lin、Robert J. DeVita

  DOI：10.1021/ml5001239

  日期：2014.6.12

  We report herein the identification of MK-4409, a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. Starting from a high throughput screening (HTS) hit, medicinal chemistry efforts focused on optimizing of FAAH inhibition in vitro potency, improving the pharmacokinetic (PK) profile, and increasing in vivo efficacy in rodent inflammatory and neuropathic pain assays.